◎ Sugi Atlas

Atlas / Drug / Metformin

Metformin

drug
On this page

Also known as LA-6023Metformin extended releaseMetforminaMetformineNN-dimethylimidodicarbonimidic diamideSID11112469SID137275802DimethyldiguanideSID144212687SID174006543MeltforminMETFORMIN HYDROCHLORIDE

Summary

Metformin (CHEMBL1431) is an approved small-molecule hypoglycemic agent (ATC A10BA02) targeting SLC47A1 and SLC47A2; indicated across 157 conditions including diabetes mellitus and gestational diabetes; with CIViC clinical evidence for 5 variant-indication associations (e.g. EGFR Mutation in lung adenocarcinoma).

At a glance

  • Status: Approved (max clinical phase 4)
  • Modality: Small molecule
  • ATC class: A10BA02
  • Targets: 2 (SLC47A1, SLC47A2)
  • Indications: 157 conditions
  • Clinical trials: 1,702
  • Precision-oncology evidence (CIViC): 5 variant–indication associations
  • Chemistry: 129.16 Da · C4H11N5

Identifiers

Drug identity and classification

FieldValue
ChEMBL IDCHEMBL1431
NameMetformin
TypeSmall molecule
Max phase4
FDA approvedyes
PubChem CID4091
ChEBICHEBI:6801
ATCA10BA02
Molecular formulaC4H11N5
Molecular weight129.16
InChIKeyXZWYZXLIPXDOLR-UHFFFAOYSA-N

SMILES: CN(C)C(=N)N=C(N)N

IUPAC name: 3-(diaminomethylidene)-1,1-dimethylguanidine

ChEBI definition: A member of the class of guanidines that is biguanide the carrying two methyl substituents at position 1.

Pharmacological roles (ChEBI): hypoglycemic agent, geroprotector.

Other ChEBI roles (chemical / environmental): xenobiotic, environmental contaminant.

Also known as: LA-6023, Metformin, Metformin extended release, Metformina, Metformine, N, N-dimethylimidodicarbonimidic diamide, metformin, SID11112469, METFORMIN, SID137275802, Dimethyldiguanide

Parent form; salt/anhydrous children: CHEMBL1703, CHEMBL3094198

Patent coverage: 51,839 distinct patent families (167,749 SureChEMBL compound mentions), from 4 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Primary targets (GtoPdb curated mechanism): the Cancer dependency column is the DepMap CRISPR fitness signal (% of screened cell lines dependent on the target).

GeneTargetActionpAffinityCancer dependencyUniProt
SLC47A1Multidrug and toxin extrusion0.5%Q96FL8
SLC47A2MATE20.6%Q86VL8

Broader ChEMBL bioactivity targets: 4 (assay-derived). Sample: Prelamin-A/C, Ferritin light chain, Alpha-1A adrenergic receptor, Dipeptidyl peptidase 4.

Bioactivity

ChEMBL activities: 3 potent at pChembl ≥ 5 of 4 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

TargetpChemblTypeValueUnitActivity ID
LMNA8.46Potency3.5nMCHEMBL_ACT_3645602
ADRA1A5.25AC505595nMCHEMBL_ACT_25137679
P027915.1Potency7943nMCHEMBL_ACT_4461649

Target pathways

Aggregated over 2 target gene(s): SLC47A1, SLC47A2.

Top Reactome pathways

4 total, by targets touching each:

PathwayTargetsGenes
Transport of small molecules2SLC47A1, SLC47A2
R-HSA-4253662SLC47A1, SLC47A2
SLC-mediated transmembrane transport2SLC47A1, SLC47A2
SLC-mediated transport of organic cations2SLC47A1, SLC47A2

Dominant GO biological processes

GO termTargets
obsolete organic cation transport2
transmembrane transport2
xenobiotic detoxification by transmembrane export across the plasma membrane2
proton transmembrane transport2
xenobiotic transmembrane transport1
putrescine transport1
xenobiotic transport1
amino acid import across plasma membrane1
L-arginine import across plasma membrane1
L-alpha-amino acid transmembrane transport1
thiamine transmembrane transport1
monoatomic cation transmembrane transport1
L-arginine transmembrane transport1

Indications & clinical

Indications

157 indications (1 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

IndicationTrial phaseMONDOEFO
diabetes mellitus4MONDO:0005015EFO:0000400
gestational diabetes3MONDO:0005406EFO:0004593
metabolic syndrome X3MONDO:0011565EFO:0000195
polycystic ovary syndrome3MONDO:0008487EFO:0000660
obesity disorder3MONDO:0011122EFO:0001073
peripheral arterial disease3MONDO:0005386EFO:0004265
colorectal adenocarcinoma3MONDO:0005008EFO:0000365
metabolic dysfunction-associated steatotic liver disease3MONDO:0013209EFO:0003095
brain neoplasm3MONDO:0021211EFO:0003833
fatty liver disease3MONDO:0004790HP:0001397
infertility disorder3MONDO:0005047EFO:0000545
metabolic disease3MONDO:0005066EFO:0000589
psoriasis3MONDO:0005083EFO:0000676
colorectal neoplasm3MONDO:0005335EFO:0004142
schizoaffective disorder3MONDO:0005487EFO:0005411
prediabetes syndrome3MONDO:0006920EFO:1001121
metabolic dysfunction-associated steatohepatitis3MONDO:0007027EFO:1001249
autosomal dominant polycystic kidney disease3MONDO:0004691EFO:1001496
colorectal carcinoma3MONDO:0024331EFO:1001951
hypertensive disorder3MONDO:0005044EFO:0000537
glucose intolerance3MONDO:0001076EFO:0002546
atherosclerosis3MONDO:0005311EFO:0003914
endometrium neoplasm3MONDO:0021251MONDO:0011962
severe acute respiratory syndrome3MONDO:0005091EFO:0000694
coronary artery disorder3MONDO:0005010EFO:0001645
hidradenitis suppurativa3MONDO:0006559EFO:1000710
intermittent vascular claudication3MONDO:0005295EFO:0003876
acute coronary syndrome3MONDO:0005542EFO:0005672
type 1 diabetes mellitus3MONDO:0005147MONDO:0005147
type 2 diabetes mellitus3MONDO:0005148MONDO:0005148
osteoarthritis3MONDO:0005178MONDO:0005178
migraine disorder3MONDO:0005277MONDO:0005277
Huntington disease3MONDO:0007739MONDO:0007739
muscular dystrophy3MONDO:0020121MONDO:0020121
epilepsy3MONDO:0005027EFO:0000474
ischemia reperfusion injury3MONDO:0005203EFO:0002687
bipolar disorder3MONDO:0004985MONDO:0004985
glaucoma3MONDO:0005041MONDO:0005041
preeclampsia3MONDO:0005081EFO:0000668
brain cancer3MONDO:0001657MONDO:0001657
long COVID-193MONDO:0100233MONDO:0100233
B-cell chronic lymphocytic leukemia2MONDO:0004948EFO:0000095
breast carcinoma2MONDO:0004989EFO:0000305
metastatic prostate carcinoma2MONDO:0004956EFO:0000196
neoplasm2MONDO:0005070EFO:0000616
prostate adenocarcinoma2MONDO:0005082EFO:0000673
prostate carcinoma2MONDO:0005159EFO:0001663
non-small cell lung carcinoma2MONDO:0005233EFO:0003060
squamous cell carcinoma2MONDO:0005096EFO:0000707
periodontitis2MONDO:0005076EFO:0000649
adenocarcinoma2MONDO:0004970EFO:0000228
pulmonary arterial hypertension2MONDO:0015924EFO:0001361
metastatic melanoma2MONDO:0005191EFO:0002617
rectal cancer2MONDO:0006519EFO:1000657
head and neck squamous cell carcinoma2MONDO:0010150EFO:0000181
chronic kidney disease2MONDO:0005300EFO:0003884
diffuse large B-cell lymphoma2MONDO:0018905EFO:0000403
atrial fibrillation2MONDO:0004981EFO:0000275
glioblastoma2MONDO:0018177EFO:0000519
hepatocellular carcinoma2MONDO:0007256EFO:0000182
carcinoma2MONDO:0004993EFO:0000313
rheumatoid arthritis2MONDO:0008383EFO:0000685
melanoma2MONDO:0005105EFO:0000756
ovarian carcinoma2MONDO:0005140EFO:0001075
plasma cell myeloma2MONDO:0009693EFO:0001378
cervical adenocarcinoma2MONDO:0005153EFO:0001416
exocrine pancreatic carcinoma2MONDO:0005192EFO:0002618
systolic heart failure2MONDO:0006993EFO:1001207
hepatitis2MONDO:0002251HP:0012115
chronic obstructive pulmonary disease2MONDO:0005002EFO:0000341
lung adenocarcinoma2MONDO:0005061EFO:0000571
small cell lung carcinoma2MONDO:0008433EFO:0000702
esophageal squamous cell carcinoma2MONDO:0005580EFO:0005922
minimally invasive lung adenocarcinoma2MONDO:0004991EFO:0000308
lung large cell carcinoma2MONDO:0003050EFO:0003050
angiosarcoma2MONDO:0016982EFO:0003968
abdominal aortic aneurysm2MONDO:0005350EFO:0004214
triple-negative breast carcinoma2MONDO:0005494EFO:0005537
pancreatic neuroendocrine tumor2MONDO:0019954EFO:1000045
neuroendocrine neoplasm2MONDO:0019496EFO:1001901
blindness (disorder)2MONDO:0001941MONDO:0001941
breast neoplasm2MONDO:0021100MONDO:0007254
lung neoplasm2MONDO:0021117MONDO:0008903
follicular lymphoma2MONDO:0018906MONDO:0018906
oral cavity squamous cell carcinoma2MONDO:0004958EFO:0000199
ulcerative colitis2MONDO:0005101EFO:0000729
peripheral neuropathy2MONDO:0005244EFO:0003100
burn2MONDO:0043519EFO:0009516
intellectual disability2MONDO:0001071HP:0001249
leprosy2MONDO:0005124EFO:0001054
heart failure2MONDO:0005252EFO:0003144
multiple sclerosis2MONDO:0005301MONDO:0005301
fragile X syndrome2MONDO:0010383MONDO:0010383
Bardet-Biedl syndrome2MONDO:0015229MONDO:0015229
frontotemporal dementia2MONDO:0017276MONDO:0017276
sex chromosome disorder of sex development2MONDO:0017975MONDO:0017975
inflammatory bowel disease2MONDO:0005265EFO:0003767
fibromyalgia2MONDO:0005546EFO:0005687
malignant pancreatic neoplasm2MONDO:0009831EFO:1000359
cerebral palsy2MONDO:0006497EFO:1000632
Parkinson disease2MONDO:0005180MONDO:0005180
sarcoidosis2MONDO:0019338MONDO:0019338
endocrine gland neoplasm2MONDO:0002082EFO:0003769
acne2MONDO:0011438EFO:0003894
oral mucosa leukoplakia2MONDO:0004844MONDO:0004844
HIV infectious disease1MONDO:0005109EFO:0000764
acute lymphoblastic leukemia1MONDO:0004967EFO:0000220
neuralgia1MONDO:0021667EFO:0005762
head and neck cancer1MONDO:0005627EFO:0006859
major depressive disorder1MONDO:0002009MONDO:0002009
breast carcinoma in situ1MONDO:0004658MONDO:0004658
diabetes insipidus1MONDO:0004782MONDO:0004782
colonic neoplasm1MONDO:0005401MONDO:0021063
obstructive sleep apnea syndrome1MONDO:0007147EFO:0003918
generalized anxiety disorder1MONDO:0001942EFO:1001892
liver disorder1MONDO:0005154HP:0002910
malaria1MONDO:0005136EFO:0001068
Duchenne muscular dystrophy1MONDO:0010679MONDO:0010679
sickle cell disease1MONDO:0011382MONDO:0011382
tuberculosis1MONDO:0018076MONDO:0018076
Li-Fraumeni syndrome1MONDO:0018875MONDO:0018875
alopecia areata1MONDO:0005340EFO:0004192
focal segmental glomerulosclerosis1MONDO:0100313EFO:0004236
diabetic retinopathy0MONDO:0005266EFO:0003770
Barrett esophagus0MONDO:0013662EFO:0000280
cardiovascular disorder0MONDO:0004995EFO:0000319
primary progressive multiple sclerosis0MONDO:0000451EFO:0008520
secondary progressive multiple sclerosis0MONDO:0000450EFO:0008522

29 further indication records had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 1,702.

Phase distribution

(phase/status distribution below is over 1,600 sampled trials of the 1,702 total).

PhaseTrials
PHASE4378
PHASE3339
PHASE2317
PHASE1276
Not specified150
PHASE2/PHASE352
EARLY_PHASE149
PHASE1/PHASE239

Top trials by phase / activity

NCTPhaseStatusTitle
NCT03570632PHASE4ACTIVE_NOT_RECRUITINGMetformin for Preeclampsia Prevention in Pregnant Women With Type 1 Diabetes Mellitus
NCT03603912PHASE4ACTIVE_NOT_RECRUITINGTargeting Risk Interventions and Metformin for Atrial Fibrillation (TRIM-AF)
NCT04407650PHASE4ACTIVE_NOT_RECRUITINGUrsodeoxycholic Acid vs Metformin in Gestational Diabetes Mellitus
NCT05120505PHASE4RECRUITINGMetformin in Children With Fragile X Syndrome
NCT05366868PHASE4ACTIVE_NOT_RECRUITINGDurable Effect of Imeglimin on the Glycemic Control in Patients With Type 2 Diabetes Mellitus
NCT05680805PHASE4ACTIVE_NOT_RECRUITINGMetabolic Responses of Metformin and Genetic Polymorphisms of SLC22A1 Gene in PCOS
NCT05744479PHASE4RECRUITINGMetformin for Antipsychotic-induced Weight Gain in Adults With Intellectual Disability
NCT06215976PHASE4RECRUITINGThe Nephroprotective Effect of Metformin With Cisplatin in Bladder Cancer
NCT06296836PHASE4RECRUITINGEffect of Continuing Versus Holding Metformin During Hospitalizations.
NCT06439758PHASE4NOT_YET_RECRUITINGEffects of First-Line Oral Hypoglycemics in Bone Markers of Treatment Naïve Saudi Adults With Type 2 Diabetes
NCT06445946PHASE4RECRUITINGDECIDE: A Comparative Effectiveness Trial of Metformin Versus Insulin for the Treatment of Gestational Diabetes
NCT06449235PHASE4NOT_YET_RECRUITINGReal-World Evaluation of Omarigliptin for Type 2 Diabetes Meliitus in Bangladesh
NCT06449833PHASE4RECRUITINGEffect of Henagliflozein on Hepatic Fat Content in Patients With T2DM and NAFLD
NCT06638671PHASE4ACTIVE_NOT_RECRUITINGShort-Term Metformin Use in Young, Healthy Adults: Impacts on Exercise Capacity
NCT06682351PHASE4NOT_YET_RECRUITINGHeterogeneity of Diabetes: Integrated Muli-Omics to Identify Physiologic Subphenotypes and Evaluate Targeted Prevention
NCT06707012PHASE4RECRUITINGEfficacy of Metformin as an Adjunct to Standard Antidepressant Therapy in Treating Depression Among Obese Patients
NCT06742710PHASE4RECRUITINGLiraglutide Treatment in Obese Infertile PCOS Women
NCT06781775PHASE4RECRUITINGGDM: Insulin with or Without Metformin?
NCT06829238PHASE4RECRUITINGAssessment of Metformin for Restoration of Immune Homeostasis in HIV+ and HIV- Individuals With a History of Injection Drug Use
NCT06846411PHASE4RECRUITINGThe EMPA-FIT Study
NCT06851962PHASE4ACTIVE_NOT_RECRUITINGImpact of Pharmacogenetic-Guided Treatment on Type 2 Diabetes.
NCT06856369PHASE4ACTIVE_NOT_RECRUITINGClinical Efficacy of 1% Metformin and Alendronate Gel in Adjunct to Fibrin in Chronic Periodontitis
NCT06862739PHASE4RECRUITINGGlycemic Control With Triple Pathway Approach Through Empagliflozin, Linagliptin and Metformin Combination
NCT06888050PHASE4RECRUITINGEfficacy and Safety of Henagliflozin Proline and Metformin Hydrochloride Extended-release Tablets (Ⅰ) Versus Metformin Tablets in Patients With New-onset Type 2 Diabetes: a Multicenter, Randomized Controlled Study
NCT06937294PHASE4RECRUITINGMetformin in Post Chronic Pancreatitis Diabetes Mellitus
NCT06959784PHASE4ENROLLING_BY_INVITATIONAssessing Incretin Therapy for Cardiovascular Risk Reduction and Diabetes Remission( ITCRDR Study)
NCT06972732PHASE4RECRUITINGA Phase IV Clinical Trial to Compare the Efficacy and Safety of Metformin+Sodium-Glucose Cotransporter 2 Inhibitor(SGLT2-i)+Thiazolidinedione (TZD) in Patients With Type 2 Diabetes
NCT07001878PHASE4RECRUITINGCannabis Potency Effects on Brain White Matter in Early Phase Psychosis
NCT07019012PHASE4RECRUITINGCofrogliptin Once Every 2 Weeks as Add-on Therapy to Metformin and Dapagliflozin Versus Daily Linagliptin in Patients With Type 2 Diabetes.
NCT07173712PHASE4NOT_YET_RECRUITINGRegimen Transition After Short-Term Intensive Insulin Therapy in Type 2 Diabetes
NCT07244003PHASE4RECRUITINGEfficacy and Safety of the Met+SGLT-2i+GLP-1RA in Patients With Type 2 Diabetes With Poor Glycemic Control
NCT07254572PHASE4RECRUITINGAnti-atherosclerotic Efficacy of Selected Antidiabetic Drugs in Patients With Coronary Artery Disease and Pre-diabetes
NCT07272967PHASE4NOT_YET_RECRUITINGMetformin in Preventing Secondary Gliosis Following Acute Thoraco-Lumbar Spinal Cord Injury
NCT07442006PHASE4RECRUITINGGlycemic Variability of Combination Therapies in T2DM
NCT07452913PHASE4ENROLLING_BY_INVITATIONMetformin, Empagliflozin With Sitagliptin vs Linagliptin in Type 2 Diabetes
NCT07485764PHASE4NOT_YET_RECRUITINGMetformin Combined With Secukinumab for Moderate-to-Severe Plaque Psoriasis in Overweight or Obese Chinese Patients
NCT00108615PHASE4COMPLETEDEffects of Insulin Sensitizers in Subjects With Impaired Glucose Tolerance
NCT00118937PHASE4COMPLETEDEffect of Metformin in Patients With Type-1 Diabetes With Inadequate Glycaemic Control by Insulin and Diet
NCT00118950PHASE4COMPLETEDEffect of Metformin Versus Repaglinide Treatment in Non-Obese Type 2 Diabetic Patients Uncontrolled by Diet
NCT00118963PHASE4COMPLETEDEffect of Repaglinide Versus Metformin Treatment in Non-Obese Patients With Type-2-Diabetes

Clinical evidence (CIViC)

Variant × indication × effect (5 predictive associations from 5 curated evidence items):

VariantIndicationEffectTherapyLevelCIViC
EGFR MutationLung AdenocarcinomaSensitivity/ResponseEGFR Tyrosine Kinase Inhibitor Therapy + MetforminCIViC BEID12074
IGF1R OverexpressionBreast CancerSensitivity/ResponseExemestane + MetforminCIViC BEID10138
KRAS MutationColorectal CancerSensitivity/ResponseMetforminCIViC BEID8301
SDHB MutationHereditary Renal Cell CarcinomaSensitivity/ResponseVandetanib + MetforminCIViC BEID7959
NRAS MutationCancerSensitivity/ResponseMetformin + TrametinibCIViC DEID1230

Pharmacology

Pharmacogenomics

No CPIC/DPWG dosing guideline, but PharmGKB curates 30 clinical and 162 variant annotation(s) for this drug (gene-keyed; see PharmGKB).

Molecules sharing ≥1 of this drug’s curated primary targets, merged from two biobtree sources and ranked by shared-target count, then clinical phase: ChEMBL clinical-stage candidates (development phase ≥2) and PubChem drug-class bioactivity (approved / known drugs acting on the target). Deduplicated by drug name; the drug’s own salt forms are excluded. Note: for a drug with few primary targets a shared-target match can reflect off-target / promiscuous binding rather than the same therapeutic mechanism — the phase ordering surfaces bona-fide therapeutics first.

68 molecules share ≥1 primary target. Top 60 by shared-target count:

MoleculeSourceStatusShared targets
BUSPIRONEChEMBL + PubChemPhase 4 (approved)SLC47A1, SLC47A2
CARVEDILOLChEMBL + PubChemPhase 4 (approved)SLC47A1, SLC47A2
CHLORHEXIDINEChEMBL + PubChemPhase 4 (approved)SLC47A1, SLC47A2
CIMETIDINEChEMBL + PubChemPhase 4 (approved)SLC47A1, SLC47A2
DIHYDROERGOTAMINEChEMBL + PubChemPhase 4 (approved)SLC47A1, SLC47A2
DIPYRIDAMOLEChEMBL + PubChemPhase 4 (approved)SLC47A1, SLC47A2
DISOPYRAMIDEChEMBL + PubChemPhase 4 (approved)SLC47A1, SLC47A2
DOMPERIDONEChEMBL + PubChemPhase 4 (approved)SLC47A1, SLC47A2
EPINASTINEChEMBL + PubChemPhase 4 (approved)SLC47A1, SLC47A2
ETHINYL ESTRADIOLChEMBL + PubChemPhase 4 (approved)SLC47A1, SLC47A2
FAMOTIDINEChEMBL + PubChemPhase 4 (approved)SLC47A1, SLC47A2
IMATINIBChEMBL + PubChemPhase 4 (approved)SLC47A1, SLC47A2
IMIPRAMINEChEMBL + PubChemPhase 4 (approved)SLC47A1, SLC47A2
IRINOTECANChEMBL + PubChemPhase 4 (approved)SLC47A1, SLC47A2
MITOXANTRONEChEMBL + PubChemPhase 4 (approved)SLC47A1, SLC47A2
ONDANSETRONChEMBL + PubChemPhase 4 (approved)SLC47A1, SLC47A2
ORPHENADRINEChEMBL + PubChemPhase 4 (approved)SLC47A1, SLC47A2
PANTOPRAZOLEChEMBL + PubChemPhase 4 (approved)SLC47A1, SLC47A2
PENTAMIDINEChEMBL + PubChemPhase 4 (approved)SLC47A1, SLC47A2
PRAZOSINChEMBL + PubChemPhase 4 (approved)SLC47A1, SLC47A2
QUINIDINEChEMBL + PubChemPhase 4 (approved)SLC47A1, SLC47A2
RIMANTADINEChEMBL + PubChemPhase 4 (approved)SLC47A1, SLC47A2
RISPERIDONEChEMBL + PubChemPhase 4 (approved)SLC47A1, SLC47A2
RITONAVIRChEMBL + PubChemPhase 4 (approved)SLC47A1, SLC47A2
TOPOTECANChEMBL + PubChemPhase 4 (approved)SLC47A1, SLC47A2
TUBOCURARINEChEMBL + PubChemPhase 4 (approved)SLC47A1, SLC47A2
VECURONIUM BROMIDEChEMBL + PubChemPhase 4 (approved)SLC47A1, SLC47A2
ZAFIRLUKASTChEMBL + PubChemPhase 4 (approved)SLC47A1, SLC47A2
BITHIONOLChEMBLPhase 4 (approved)SLC47A1, SLC47A2
DABIGATRANChEMBL + PubChemPhase 3 (approved)SLC47A1, SLC47A2
CAMOSTATChEMBLPhase 3SLC47A1, SLC47A2
GABEXATEChEMBLPhase 3SLC47A1, SLC47A2
INDINAVIRChEMBLPhase 3SLC47A1, SLC47A2
NIFEKALANTChEMBLPhase 3SLC47A1, SLC47A2
AripiprazolePubChemApprovedSLC47A1, SLC47A2
PimozidePubChemApprovedSLC47A1, SLC47A2
AMANTADINEChEMBL + PubChemPhase 4 (approved)SLC47A1
CLONIDINEChEMBL + PubChemPhase 4 (approved)SLC47A1
SPIRONOLACTONEChEMBL + PubChemPhase 4 (approved)SLC47A1
SUMATRIPTANChEMBL + PubChemPhase 4 (approved)SLC47A1
TELMISARTANChEMBL + PubChemPhase 4 (approved)SLC47A1
ASTEMIZOLEChEMBLPhase 4 (approved)SLC47A1
GRANISETRONChEMBLPhase 4 (approved)SLC47A1
LEVOFLOXACINChEMBLPhase 4 (approved)SLC47A1
MARAVIROCChEMBLPhase 4 (approved)SLC47A1
NOSCAPINEChEMBLPhase 4 (approved)SLC47A1
RANITIDINEChEMBLPhase 4 (approved)SLC47A1
TACRINEChEMBLPhase 4 (approved)SLC47A1
CORTISONEChEMBL + PubChemPhase 3 (approved)SLC47A1
AFIMETORANChEMBLPhase 2SLC47A2
azacitidinePubChemApprovedSLC47A1
CetirizinePubChemApprovedSLC47A1
CiclopiroxPubChemApprovedSLC47A1
DexamethasonePubChemApprovedSLC47A1
DiclofenacPubChemApprovedSLC47A1
EnalaprilPubChemApprovedSLC47A1
ErythromycinPubChemApprovedSLC47A1
FurosemidePubChemApprovedSLC47A1
IndomethacinPubChemApprovedSLC47A1
IrbesartanPubChemApprovedSLC47A1

About this page

Generated deterministically by Sugi Atlas from primary biomedical databases via BioBTree. Every record on this page traces to a primary source.

Generated
Atlas version
v1.1.2
BioBTree
v2.0.2

Sources 30

This page pulls from 30 datasets indexed by BioBTree:

chebichembl_activitychembl_moleculechembl_targetcivic_evidenceclingen_dosageclinical_trialsdepmapefoensemblentrezgogoparentgtopdbgtopdb_interactiongtopdb_ligandhgncmeshmondomsigdbpatent_compoundpharmgkbpharmgkb_guidelinepubchempubchem_activityreactomereactomeparentrefseqtranscriptuniprot